cetuximab,rg6330
roche,eli lilly
['rectal', 'gdc-6036', 'colorectal', 'cetuximab']
incredible orr 62% in gdc-6036 combo w/ cetuximab for kras g12c mut colorectal cancer which represents ~3% of the us patient popn. #aacr23 looking forward to drug development targeting kras g12d/v that represents ~22% of patients w/ colorectal cancer! 
@OncoKB Lead Scientist @MSKPathology Assistant Member @sloan_kettering cancer biologist. Mother, wife of @JPayneWrites, daughter & sister. tweets are mine.